Nasdaq tmdx

The latest price target for . TransMedics Gr (

On October 2, 2023, Stephen Gordon, the Chief Financial Officer of TransMedics Group Inc (NASDAQ:TMDX), sold 5,000 shares of the company.This move is part of a larger trend, as over the past year ...The list of insiders at TransMedics Group includes Abrams Capital Management, L.P, David Weill, Edward M Basile, Edwin M Kania Jr, James R Tobin, John F Carey, John F Sullivan, Laura Damme, Miriam Provost, Stephanie Lovell, Stephen Gordon, Tamer I Khayal, and Waleed H Hassanein.

Did you know?

ANDOVER, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for ...Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 5, 2023, TransMedics granted non-qualified stock options to purchase an aggregate of 105,119 shares of its common stock and an …TransMedics Group Inc (NASDAQ: TMDX) said the FDA has temporarily postponed the Adcom meeting to review the company's premarket approval application for its OCS Heart to allow time to review ...The forecasts range from a low of 74.74 to a high of $99.75. The average price target represents an increase of 8.75% from its latest reported closing price of 77.85. See our leaderboard of ...Nov 7, 2023 · 57.37. -0.89. -1.53%. TransMedics Group, Inc. (NASDAQ:TMDX) Q3 2023 Earnings Call Transcript November 6, 2023 Operator: Good afternoon, and welcome to TransMedics Third Quarter 2023 Earnings ... That's exactly what TransMedics Group (NASDAQ: TMDX) is doing in organ transplantation. For years, cold storage has been the standard way of preserving donor organs.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and ...TransMedics Gr Stock (NASDAQ:TMDX), Short Interest Report. Short interest for TransMedics Gr gives investors a sense of the degree to which investors are betting on the decline of TransMedics Gr's ...Nasdaq. 14,258.49-23.27 (-0.16%) ... (NASDAQ:TMDX) future prospects. TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for ...Nov 30, 2023 · See the latest TransMedics Group Inc stock price (TMDX:XNAS), related news, valuation, ... TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) US89377M1099. TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. TMDX Pre-Market Quotes. Data is delayed at least 15 minutes. Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the ... Feb 24, 2023 · NASDAQ: TMDX TransMedics Group. Market Cap. $2B. Today's Change (2.92%) $1.95. Current Price. $68.70. Price as of November 17, 2023, 4:00 p.m. ET. ... (TMDX 2.92%). This high-growth stock has been ... Nasdaq | TMDX U.S.: Nasdaq TransMedics Group Inc. Watch list NEW Set a price target alert Open Last Updated: Nov 24, 2023 1:00 p.m. EST Delayed quote $ 70.34 1.39 …TransMedics Group, Inc. Prices $400 Million of Convertible Senior Notes Due 2028. ANDOVER, Mass. , May 8, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st... 7 months ago - PRNewsWire.TransMedics (TMDX) reported $66.43 million in revenue for the quarter ended September 2023, representing a year-over-year increase of 158.7%. EPS of -$0.12 for the same period compares to -$0.25 a ...ANDOVER, Mass., Sept. 29, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...२०२३ अगस्ट २ ... (NASDAQ: TMDX), including its EVOSS heart and lung and LifeCradle heart perfusion assets. BTL will use the proceeds from the divestiture of ...TMDX stock has a Moderate Buy consensus rating based on two Buy and one Hold recommendations. However, due to the recent rally in its stock price, analysts’ average price target of $66.67 ...Nov 7, 2023 · That number of contracts represents approximately 515,700 underlying shares, working out to a sizeable 63% of TMDX's average daily trading volume over the past month, of 819,150 shares. Feb 22, 2023 · TransMedics Group Inc (Symbol: TMDX) saw options trading volume of 3,088 contracts, representing approximately 308,800 underlying shares or approximately 85.5% of TMDX's average daily trading ... ANDOVER, Mass., Nov. 11, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...US89377M1099. TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. Maybe you’ve never invested before. Maybe you have no TransMedics Reports Inducement Grants Under NASDAQ Listing 10 Jun, 2021, 10:35 ET. ANDOVER, Mass., June 10, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant ... As of May 11, 2023, the average one-year price target for Aug 15, 2023 · Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in TransMedics Group Inc (Symbol: TMDX), where a total of 3,622 contracts have traded so ... Avid Technology, Inc. (NASDAQ:AVID) is the most popular sto

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure ...TransMedics (Nasdaq:TMDX) shares got a massive boost today on first-quarter sales that were 64% higher than the consensus forecast.. TMDX shares were up more than 30% at $28.44 apiece by midday ...TransMedics Group press release ( NASDAQ: TMDX ): Q1 GAAP EPS of -$0.08 beats by $0.19. Revenue of $41.6M (+161.6% Y/Y). Sees FY 2023 revenue of $160 million to $170 million. TMDX had guided FY ...

Find the latest SEC Filings data for TransMedics Group, Inc. Common Stock (TMDX) at Nasdaq.com.Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. Close Trending …Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in...…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. ANDOVER, Mass., Sept. 29, 2021 /PRNewswire/ -- Tran. Possible cause: Sep 8, 2021 11:17AM EDT. TransMedics Group, Inc. TMDX recently announced its receip.

Earnings for TransMedics Group are expected to decrease in the coming year, from ($0.34) to ($0.67) per share. TransMedics Group has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 28th, 2024 based off prior year's report dates. Read More.Nov 23, 2023 · The stock of Transmedics Group Inc (NASDAQ: TMDX) has increased by 1.56 when compared to last closing price of 67.89. Despite this, the company has experienced a 5.12% gain in its stock price over the last five trading sessions. The Motley Fool reported 2023-11-09 that TransMedics Group’s transplant organ retrieval and delivery business is accelerating […]

Based on analysts offering 12 month price targets for TMDX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . Nov 28, 2023 · Shares of TransMedics (NASDAQ:TMDX) surged after the company reported very strong third quarter results and raised the full-year guidance that includes the initial positive impact from the ... ANDOVER, Mass., Aug. 9, 2021 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...

ANDOVER, Mass., May 06, 2019 (GLOBE NEWSWIRE) We feel now is a pretty good time to analyse TransMedics Group, Inc.'s (NASDAQ:TMDX) business as it appears the company may be on the cusp of a considerable accomplishment. TransMedics Group, Inc ...Nov 7, 2023 · That number of contracts represents approximately 515,700 underlying shares, working out to a sizeable 63% of TMDX's average daily trading volume over the past month, of 819,150 shares. TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a TipRanks | Stock Market Research, News and Analyst Forecas TransMedics Group, Inc. (NASDAQ:TMDX) is a Massachusetts-based commercial-stage medical technology company, engaged in transforming organ transplant therapy for end-stage organ failure patients in ... Market Data Stock Lists Headlines About NASDAQ:TMDX TransM (RTTNews) - The following are some of the healthcare companies that reported their financial results for the quarter ended June 30, 2022, yesterda... (RTTNews) - The following are some of the healthcare companies that reported their financi...May 11, 2023 · Fintel reports that on May 18, 2023, Canaccord Genuity maintained coverage of Transmedics Group (NASDAQ:TMDX) with a Buy recommendation.. Analyst Price Forecast Suggests 20.80% Upside. As of May ... 276,036. 5.445315. Back to TMDX Overview. NASDAQ, Inc. short interesNov 29, 2023 · TransMedics Group, Inc. Prices $4TransMedics Group, Inc. (TMDX) NasdaqGM - NasdaqGM Real Time Nasdaq. 14,258.49-23.27 (-0.16%) ... (NASDAQ:TMDX) future prospects. TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for ... 23.36M. AMZN. 146.71. +1.95%. 45.70M. View today's View real-time TMDX stock price and news, ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with volume of at least 50,000. That's exactly what TransMedics Group (NASDAQ: [ANDOVER, Mass., Aug. 29, 2022 /PRNewswire/ -- TransTherapeuticsMD, Inc. Common Stock (TXMD) Stock Quotes - Nasdaq off Charles Schwab Investment Management Inc. raised its position in TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) by 3.1% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 240,998 shares of the company’s stock after buying an additional 7,334 shares during …